Expert Interview
Discussing the recent results from the phase 3 KEYNOTE-A18 trial, studying Merck's Keytruda in combination with EBRT and chemotherapy followed by brachytherapy, for patients with cervical cancer.
Ticker(s): MRKInstitution: Massachusetts General Hospital
- manages 200 patients with ovarian cancer
- comfortable discussing the Phase 1 data for ubamatamab presented at ESMO
- Gynecologic Oncologist in full-time practice; Professor of Obstetrics, Gynecology and Reproductive Biology at Harvard Medical School. Dr. del Carmen is also Chief Medical Officer of the Massachusetts General Physicians Organization.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
